Affiliation:
1. Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
2. Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada
3. Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA
Abstract
Abstract
Background
Little is known about the effect of the COVID-19 pandemic on antimicrobial consumption worldwide.
Objectives
To describe the impact of the WHO Global Action Plan on Antimicrobial Resistance (GAP-AMR) on antimicrobial consumption pre-pandemic and to evaluate the impact of the COVID-19 pandemic on antimicrobial consumption worldwide.
Methods
A cross-sectional time-series analysis using a dataset of monthly purchases of antimicrobials (antibiotics, antivirals and antifungals) from August 2014 to August 2020. Antimicrobial consumption per 1000 population was assessed pre-pandemic by economic development status using linear regression models. Interventional autoregressive integrated moving average (ARIMA) models tested for significant changes with pandemic declaration (March 2020) and during its first stage from April to August 2020, worldwide and by country development status.
Results
Prior to the pandemic, antimicrobial consumption decreased worldwide, with a greater apparent decrease in developed versus developing countries (−8.4%, P = 0.020 versus −1.2%, P = 0.660). Relative to 2019, antimicrobial consumption increased by 11.2%, P < 0.001 in March 2020. The greatest increase was for antivirals in both developed and developing countries (48.2%, P < 0.001; 110.0%, P < 0.001) followed by antibiotics (6.9%, P < 0.001; 5.9%, P = 0.003). From April to August 2020, antimicrobial consumption decreased worldwide by 18.7% (P < 0.001) compared with the previous year. Specifically, antibiotic consumption significantly decreased in both developed and developing countries (−28.0%, P < 0.001; −16.8%, P < 0.001).
Conclusions
The global decrease in antimicrobial consumption pre-pandemic suggests a positive impact of the WHO GAP-AMR. During the pandemic, an initial increase in antimicrobial consumption was followed by a decrease worldwide. AMR plans should specify measures to ensure full implementation of AMR efforts during health crises such as the COVID-19 pandemic.
Publisher
Oxford University Press (OUP)
Subject
Infectious Diseases,Pharmacology (medical),Pharmacology,Microbiology (medical)
Reference33 articles.
1. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015;Klein;Proc Natl Acad Sci U S A,2018
2. Assessment of WHO antibiotic consumption and access targets in 76 countries, 2000–15: an analysis of pharmaceutical sales data;Klein;Lancet Infect Dis,2021
3. WHO member states adopt global action plan on antimicrobial resistance;Eurosurveillance Editorial Team;Eurosurveillance,2015
4. Antimicrobial resistance–SEA/RC68/R3;WHO,2015
5. Monitoring global progress on antimicrobial resistance: tripartite AMR country self-assessment survey (TrACSS) 2019–2020: global analysis report;WHO,2021
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献